Sangamo Therapeutics, Inc.
SGMO
$0.44
$0.00-0.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -74.77% | 34.68% | -30.78% | -319.23% | 129.54% |
| Total Depreciation and Amortization | 0.05% | -1.40% | -9.88% | 0.38% | -17.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.72% | -13.26% | 1.09% | -11.12% | -56.51% |
| Change in Net Operating Assets | 203.53% | -2,919.48% | -100.50% | 489.76% | -28,207.14% |
| Cash from Operations | -56.94% | 30.56% | -680.33% | -128.50% | 143.74% |
| Capital Expenditure | -166.67% | -- | -- | -32.17% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 324.14% | 174.02% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -166.67% | -- | -- | 468.24% | 83.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -32.94% | 180.22% | 43.68% | -- | -- |
| Repurchase of Common Stock | 36.43% | 81.14% | -912.27% | -8.37% | 61.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -32.89% | 251.78% | 16.35% | 3,543.84% | 61.91% |
| Foreign Exchange rate Adjustments | -98.46% | 113.94% | 156.83% | -299.56% | 538.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -170.77% | 178.65% | -716.05% | -78.96% | 146.88% |